Aptar Pharma, a leader in drug delivery and active material science solutions and services, has acquired the worldwide rights to clinical stage drug developer Pharmaxis’ proprietary Orbital inhaler, a unique device designed to deliver high payload dry powder to the lungs.   The Orbital technology helps meet an increasing global need to deliver high doses of drugs, such as antibiotics, to the lungs and allows powder payloads of up to 400mg to be inhaled by patients in divided doses without the ...